MedPath

The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?

Conditions
Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom
Interventions
Drug: ACE inhibitor
Registration Number
NCT04322786
Lead Sponsor
University College, London
Brief Summary

The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed ACEI compared to those not prescribed ACEI.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1302508
Inclusion Criteria
  • We identify individuals aged 18 years or older and registered in the current primary care practice for at least one year.
Exclusion Criteria
  • We exclude individuals with a prior history of influenza and viral pneumonia before study entry.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ACEI userACE inhibitorIndividuals with an ACEI prescription in the study population.
Primary Outcome Measures
NameTimeMethod
Incidence of influenzaJan 1st 1998 - May 31st 2016
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath